The European Institute of Innovation & Technology (EIT) is an independent institution of the European Union, founded in 2008 to promote innovation and entrepreneurship across Europe. Since 2014, the network initiative has also been active in the field of health in Europe. EIT Health is currently working with around 130 members in a "public-private partnership" to find solutions to the major healthcare challenges of our time. Leading companies, public institutions as well as renowned universities and research institutions are working together with start-ups and SMEs in innovative programmes and projects to develop new products and services that promote a sustainable health economy in Europe. The aim of EIT Health is to close the innovation gap in the life science sector.
EIT Health Austria is one of a total of eight EIT Health centres in Europe and currently supports 15 members from industry, research and education in Austria, including Boehringer Ingelheim, Med Uni Graz, the Ludwig Boltzmann Gesellschaft, as well as start-ups and SMEs in the development of groundbreaking innovations in healthcare. With the "HealthGateway.Austria" project, EIT Health Austria also operates an innovation laboratory in Vienna funded by the FFG, which increasingly integrates Austrian companies and organisations in the life science sector into the activities of EIT Health.
Altus Biolabs is an analytical laboratory specialized in the analysis of cannabinoids in various cannabis products as well as the development of analytical assays for the detection of plant pathogens. Our goal is to ensure the quality and safety of cannabis products on the market and to help their producers streamline their processes
Core areas of expertise are design, development and production of real-time PCR-based tests for the detection of various pathogens such as bacteria, viruses, fungi and parasites, for applications in human and veterinary medicine.
RIANA Therapeutics' approach to drug discovery is based on its proprietary platform technology for discovering compounds that target cancer-promoting protein-protein interactions (PPIs). Using this novel approach, RIANA is searching for inhibitors that block the formation of specific oncogenic PPIs. RIANA is currently working to develop new compounds that specifically target acute myeloid leukemia (AML) as well as other blood cancers and certain types of solid tumors.
CEBINA uniquely supports life science entrepreneurs and early-stage start-up companies in developing cutting-edge biotech projects
IT Support for Life Science. Cybersecurity, Computational Biology )Bioinformatics), "Big Pharma" digital Compliance
In 2019, the healthcare policy and communication expert Michael Eipeldauer founded the management and public affairs consulting company Eipeldauer-Consulting e.U.
CALYXHA develops novel small-molecule anti-inflammatory drugs
MAG – Molecular Architecture Group – brings together scientists with decades-long experience in NMR applications for drug design
Karyon Biopharma Consulting e.U. supports clients during non-clinical drug development.
Services encompass:
• Design of product-tailored non-clinical development plans for medicinal products to enable CTA/IND (small molecules, biologics, ATMPs (cell- and vector-based), vaccines)
• Support in CRO selection and placement of studies at CROs (request for proposals for complex non-clinical programs, CRO comparisons up to placement and elaboration of detailed study plans)
• Involvement in study designs for non-GLP and GLP studies, monitoring and study report reviews, including data interpretation
• Support for regulatory questions: early regulatory strategy, preparation and conduct of regulatory interactions with regulatory Authorities, including coordination and moderation of Scientific Advice Meetings (national Authorities / EMA / FDA)
• Scientific writing of a broad range of (regulatory) documents, including non-clinical parts of Briefing Documents for Scientific Advice Meetings, IBs, non-clinical summaries and overviews of CTDs / INDs, non-clinical ATMP certification dossiers
• Preparation of different types of toxicological risk assessments / expert statements
• Preparation of biological evaluation reports (BERs) for substance-based medical devices
For further details, please contact me at a.guenzl@karyon-consulting.com
The name says it all: Open Science - Life Sciences in Dialogue is all about making life sciences available to everyone. The association works in a wide variety of communication projects – from discussions to laboratory workshops, teacher training and citizen science projects – to stimulate discussion about life science topics and bring scientists together with school pupils, teachers and anyone else interested in learning more.
We are Experts at Translating Complex Science Into the Real-World: bridge the gap between science and people, manufacturers and regulators. At BioSciPons we work at the interface of regulatory, medical affairs and communication. We are experts at translating complex science into precise and clear communication contents (e.g., Reports, Technical files, Investigator Brochures, Medical Manuscripts, Articles, Instructions for Use, User Manuals, Video Scripts, Posters,...). Our aim is to explain the relevance and ramifications of your medical device or your scientific findings, while maintaining regulatory correctness and scientific acumen. We want to bridge the gap between R&D, regulatory agencies, healthcare and users/consumers - hence our bridge as a logo. To cross this bridge two things are needed: a high level of communication, and a deep understanding of clinical science & regulations. As clinical scientists, we understand the details. As communicators, we can transform your complex clinical data and translate it into a consistent message, that can then be tailored to each target audience (e.g., regulators, peer-reviewers, board executives, users/consumers/patients). With our "outside-of-the-box" approach, we can foresight the gaps in your clinical data; and prepare your product for the "curve ahead". We not only want you to cross the bridge, but help you go forward on a straight highway. BioSciPons works from any starting point for a customised service. We personalise our services to fit the needs of each individual medical/biotechnology product through PhD knowledge.
Expertise: Digital Therapeutics, Artificial Intelligence and Machine Learning Software as Medical Device, Injectables/Implantable's Class III.
Marinomed Biotech AG is a biopharmaceutical company focused on inventing, developing, and partnering clinically meaningful therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders. Since its foundation in 2006, Marinomed has launched two powerful technologies (Carragelose® and Marinosolv®) with promising product candidates in the pipeline and a great potential for developing drugs that target diseases with high unmet medical need.
BioPeak offers technology consulting for biotech and pharma. BioPeak services include data strategy, data architecture and data analysis solutions, tailored software solutions for your business processes, consultation in bioimaging solutions and hardware engineering for your R&D needs.
Festo – das Unternehmen
Festo Österreich ist Marktführer in der Automation mit Pneumatik und Elektrik sowie der technischen Aus- und Weiterbildung. Das Unternehmen ist für den Vertrieb in Österreich zuständig und bildet zusätzlich die Drehscheibe für die mittel- und osteuropäischen Konzernaktivitäten sowie für die Produkt- und Systementwicklung. Zu Festo Österreich gehören 120 Mitarbeiterinnen und Mitarbeiter – insgesamt beschäftigt Festo in 60 Ländern etwa 20.800 Personen. Mit rund 33.000 Katalogprodukten in einigen hunderttausend Varianten nimmt Festo weltweit eine führende Rolle in der Industrie- und Prozessautomation ein. Jährlich investiert der Konzern rund 7 % seines Umsatzes (2022 rd. 3,81 Mrd. Euro) in Entwicklung und Forschung. In Österreich betreibt Festo eine eigene Forschungseinheit für industrielle Steuerungstechnik und ein Technic and Application Center, das Kunden bei ihrer Entwicklungstätigkeit unterstützt. Corporate Educational Responsibility: Das Familienunternehmen nimmt seine gesellschaftliche Verantwortung vor allem im Bildungsbereich sehr engagiert wahr – beispielsweise durch einen eigenen Bildungsfonds und die Vergabe von Experimentierboxen an Schulen.
www.festo.at
LISAvienna is the cluster platform for life sciences in Vienna, which was set up at the interface of Austria Wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Labour and Economy and the City of Vienna, it contributes to the further development of the industry. LISAvienna supports innovative companies in the fields of biotechnology, pharmaceuticals, medical products and digital health that develop new products, services and processes in Vienna and bring them to market internationally. The platform connects these companies with development partners and lead customers. As a thought leader, LISAvienna provides a basis for decision-making to strengthen the life sciences in Vienna and helps to position Vienna as one of Europe's leading innovation centers.
AURIMOD is a commercial stage medical device company founded to disrupt global healthcare by patient-tailored electroceutical pain therapies. We develop products for the minimal-invasive electrical stimulation of the auricular branch of the vagus nerve. By this autonomic stimulation we harness the bodies’ own mechanisms to fight the disease sustainably with a clinically proven effect.
Holloid provides devices and cloud-based software for automated high-throughput holographic microsopcy. It enables users to image, and categorize microorganisms (bacteria, mammalian cells, yeast cells, micro algae) and microparticles (microplastics, etc.) and count them to monitor their presence and growth 24/7.
With this technology, organizations can accelerate research, optimize processes and issue very early warnings about contaminations. This is valuable in in research, development and production. Quality and bioprocess control in red, white and green biotechnology can benefit from unprecedented insights, automated analysis, 1,000 faster reliable insights, 1,000,000 higher throughput. This helps create better medication and products sooner, and accelerate the transition to more sustainable value chains across industries.